Patents by Inventor Uday S. Gogate

Uday S. Gogate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8871227
    Abstract: A process for formulating certain epothilones and analogs thereof for parenteral administration is provided wherein the pH of the formulation for administration can be controlled to enhance the stability and thus, potency of the epothilone, or analog thereof.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: October 28, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thomas A. Haby, Uday S. Gogate, Vijay H. Naringrekar
  • Publication number: 20100016385
    Abstract: A process for formulating certain epothilones and analogs thereof for parenteral administration is provided wherein the pH of the formulation for administration can be controlled to enhance the stability and thus, potency of the epothilone, or analog thereof.
    Type: Application
    Filed: September 11, 2009
    Publication date: January 21, 2010
    Inventors: Thomas A. Haby, Uday S. Gogate, Vijay H. Naringrekar
  • Publication number: 20090291913
    Abstract: An injectable Factor Xa inhibitor formulation is provided which includes the Factor Xa inhibitor razaxaban or apixaban, a solubilizing agent which is a substituted ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBE-CD) or hydroxypropyl-?-cyclodextrin (HPB-CD), and water. A method for preventing or treating venous thrombosis, deep venous thrombosis and acute coronary syndrome employing the above formulation is also provided.
    Type: Application
    Filed: August 4, 2009
    Publication date: November 26, 2009
    Applicant: Bristol-Myers Squibb Company
    Inventors: Munir N. Nassar, Uday S. Gogate, Timothy M. Malloy
  • Patent number: 5703111
    Abstract: This invention relates to a stable, easy to constitute, injectable formulation of anticancer agent BMY-25067. More specifically, the present invention concerns a formulation of BMY-25067 obtained from lyophilizing a solution comprising up to 4 mg of BMY-25067 per mL of 65% t-butanol/water, further comprising about 2% PVP (K-12 or K-17), optionally comprising pharmaceutically acceptable carrier(s).
    Type: Grant
    Filed: December 4, 1996
    Date of Patent: December 30, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Uday S. Gogate, Shreeram N. Agharkar, Lawan Phusanti
  • Patent number: 5504102
    Abstract: A stabilized pharmaceutical composition containing paclitaxel, teniposide, camptothecin or other antineoplastic agent susceptible to degradation during storage is produced using a solvent system containing a low carboxylate anion content. The solvent system is a mixture of ethanol and a polyoxyethylated castor oil. The polyoxyethylated castor oil is treated with an acid or contacted with alumina to reduce the carboxylate anion content of the solvent. The low carboxylate anion content of the solvent provides extended shelf life and lower amounts of degradation by-products.
    Type: Grant
    Filed: January 18, 1995
    Date of Patent: April 2, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shreeram N. Agharkar, Uday S. Gogate